| 0:00:03 | breast cancer consumers to remain the most common cancer diagnosed in women in the united | 
|---|
| 0:00:08 | states and is the same leading cause of cancer that in women | 
|---|
| 0:00:13 | the current lifetime risk of a woman developing breast cancer is one and eight or | 
|---|
| 0:00:17 | twelve point three percent | 
|---|
| 0:00:19 | several breast cancer risk factors have been identified over the years | 
|---|
| 0:00:24 | some of them up modifiable while others are not | 
|---|
| 0:00:27 | the objective of this review is just summarize the vector strategies directed at reducing the | 
|---|
| 0:00:33 | risk of breast cancer which are in thilo's an integrated approach in one thing identification | 
|---|
| 0:00:39 | of high risk women if a screening reference as well as nutritional pharmacological and surgical | 
|---|
| 0:00:45 | management | 
|---|
| 0:00:47 | so risk assessment tools the most common being together model | 
|---|
| 0:00:51 | clinicians determine the quantitative risk of breast cancer | 
|---|
| 0:00:55 | the role of selective oestrogen receptor modulator to marks the fan and scheme documented in | 
|---|
| 0:01:01 | change was established by several clinical trials | 
|---|
| 0:01:04 | such as the and f a b p one trial | 
|---|
| 0:01:07 | subsequently we lost if we also emerge as an option to emox of an with | 
|---|
| 0:01:12 | this reduction in the incidence of breast cancer reported in the star trial | 
|---|
| 0:01:18 | currently the united states to mark the fan | 
|---|
| 0:01:21 | and velocity are f t approved for this indication | 
|---|
| 0:01:25 | more recently a little bit ace inhibitors such as x m s t and announced | 
|---|
| 0:01:29 | result were shown to reduce the incidence of breast cancer in the map three and | 
|---|
| 0:01:34 | i was to trials respectively and may serve as an alternative to the selected oestrogen | 
|---|
| 0:01:40 | receptor modulator is what about to be favourable side effect profile | 
|---|
| 0:01:45 | the potential adverse effects of the schema preventive agents such as individual high publisher and | 
|---|
| 0:01:51 | trombone body disease with a marks the phone or a structure as hot flashes and | 
|---|
| 0:01:57 | all stripper roses with a limiting is inhibitors must be discussed with the patient before | 
|---|
| 0:02:02 | deciding on this approach | 
|---|
| 0:02:04 | it is estimated that over two million women in the united states could benefit from | 
|---|
| 0:02:08 | cuba prevention to reduce the risk of breast cancer however in reality it's uses rather | 
|---|
| 0:02:14 | limited possible explanations the disinclude | 
|---|
| 0:02:18 | difficulties identifying the ideal candidates for this approach | 
|---|
| 0:02:22 | decreased awareness amongst health care providers | 
|---|
| 0:02:25 | and high risk women and concerns about the potential adverse effects in the absence of | 
|---|
| 0:02:29 | the diagnosed cancer | 
|---|
| 0:02:31 | identifying the optimal candidate speaking about prevention strategies | 
|---|
| 0:02:35 | and it is to be challenging | 
|---|
| 0:02:37 | is the existing breast cancer risk assessment models do not incorporate or non risk factors | 
|---|
| 0:02:43 | for breast cancer and there is a significant variability in the overall design and points | 
|---|
| 0:02:48 | and inclusion criteria across clinical trials | 
|---|
| 0:02:52 | although there is no conclusive evidence to suggest the protective role of specific directory components | 
|---|
| 0:02:58 | alcohol consumption | 
|---|
| 0:02:59 | and obesity are associated with an increased breast cancer risk does lifestyle changes can you | 
|---|
| 0:03:05 | to a lower risk of developing breast cancer | 
|---|
| 0:03:09 | such approaches including bilateral risk reduction mastectomy | 
|---|
| 0:03:13 | and starting correctable | 
|---|
| 0:03:15 | i usually limited to agreement with the red terry predisposition to developing breast scan | 
|---|